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study question: How has the interface between genetics and assisted reproduction technology (ART) evolved since 2005?
summary answer: The interface between ART and genetics has become more entwined as we increase our understanding about the
genetics of infertility and we are able to perform more comprehensive genetic testing.
what is known already: In March 2005, a group of experts from the European Society of HumanGenetics and European Society of
Human Reproduction and Embryology met to discuss the interface between genetics and ART and published an extended background paper,
recommendations and two Editorials.
study design, size, duration: An interdisciplinary workshopwas held, involving representatives of both professional societies and
experts from the European Union Eurogentest2 Coordination Action Project.
participants/materials, setting, methods: In March 2012, a group of experts from the European Society of Human Gen-
etics, the European Society of Human Reproduction and Embryology and the EuroGentest2 Coordination Action Project met to discuss devel-
opments at the interface between clinical genetics and ART.
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main results and the role of chance: As more genetic causes of reproductive failure are now recognized and an increasing
number of patients undergo testing of their genome prior to conception, either in regular health care or in the context of direct-to-consumer
testing, the need for genetic counselling and PGD may increase. Preimplantation genetic screening (PGS) thus far does not have evidence
from RCTs to substantiate that the technique is both effective and efﬁcient. Whole genome sequencing may create greater challenges both in
the technological and interpretational domains, and requires further reﬂection about the ethics of genetic testing in ART and PGD/PGS. Diag-
nostic laboratories shouldbe reporting their results according to internationally accepted accreditation standards (ISO15189). Further studies are
needed in order to address issues related to the impact of ART on epigenetic reprogramming of the early embryo.
limitations, reasons for caution: The legal landscape regarding assisted reproduction is evolving, but still remains very hetero-
geneous and often contradictory. The lack of legal harmonization and uneven access to infertility treatment and PGD/PGS fosters considerable
cross-border reproductive care in Europe, and beyond.
wider implicationsof thefindings: This continually evolving ﬁeld requires communicationbetween the clinical genetics and IVF
teams and patients to ensure that they are fully informed and can make well-considered choices.
study funding/competing interest(s): Fundingwas received fromESHRE, ESHGandEuroGentest2EuropeanUnionCoord-
ination Action project (FP7 – HEALTH-F4-2010-26146) to support attendance at this meeting.
Key words: assisted reproduction technology / European Society of Human Genetics / European Society of Human Reproduction and
Embryology / reproductive genetics / IVF
Introduction
In 2004, the Public and Professional Policy Committee (PPPC) of the
European Society of Human Genetics (ESHG) felt the need for profes-
sional recommendations on how to use assisted reproduction technol-
ogy (ART) safely and reliably from the genetic point of view, as well as
issuing guidelines on acceptable (genetic) goals of ART treatment and
its prioritization in the European healthcare systems. It was thus
decided to approach the European Society of Human Reproduction
and Embryology (ESHRE) to undertake such work together. After a
number of preparatory get-togethers of a working group, a joint
ESHG/ESHRE meeting was held in Seville, Spain, from 31 March to 1
April 2005, and a paper summarizing the meeting was published (Soini
et al., 2006).
In 2012, an expert group of ESHRE and ESHG representatives met
again to assess the changes that had occurred in the ﬁeld for the past 7
years and to update the common background document, wherever
needed. This commentary presents a summary of the meeting which is
also presented in full (Harper et al., 2013).
European Directives
Recent European Union (EU) directives have had a signiﬁcant impact on
ART. In particular, the EU Tissue and Cells Directive (EUTCD; currently
under revision) (EC-Dir23, 2004) and the supplementing technical direc-
tives 2006/17/EC (EC-Dir17, 2006) and 2006/86/EC (EC-DIr86,
2006;Willemen et al., 2012) have led to new safety and quality standards
for clinical and laboratory procedures performed within IVF. Most Euro-
pean countries already transposed them into their respective national
legislations, thus regulating procurement, testing, processing, storage,
distribution and import/export of reproductive cells and tissues. More-
over, the EUDirective 98/79/EC (EC-Dir98-IVD, 1998) on in vitro diag-
nostic medical devices, known as the ‘IVD Directive’ is also currently
under revision and may have a signiﬁcant effect on the ﬁeld of genetic
testing and its interface with ART.
Cross-Border Reproductive Care
Cross-border reproductive care (CBRC) refers to the care of patients
who cross borders in search of reproductive treatment. Recent Euro-
pean data from the ﬁrst international European study published by the
CBRC ESHRE Taskforce (Shenﬁeld et al., 2010) conﬁrmed that the
main reasons for travelling were legal restrictions based on prohibition
of the technique per se, or because of inaccessibility due to the character-
istics of the patients (like age, sexual orientation or civil status). It also
highlighted that people tend to travel to the nearest country where the
required technique is available, such as Germans seeking oocyte dona-
tion in theCzechRepublic, or French lesbian couples donor insemination
in Belgium.
Concerned about the joint professional responsibility of all involved in
ART, theCBRC ESHRE Taskforce also published aGood Practice Guide
for CRBC, for patients and collaborators involved in the child project,
including gamete donors and surrogates (Shenﬁeld et al., 2011).
Other challenges are also looming, as oocyte banking is becoming
much more efﬁcient thanks to vitriﬁcation (Cobo et al., 2008). This
means that eggs have started to cross borders, making it more difﬁcult
to check the conditions of gamete donation.
Genetics of Female Infertility
For the more common conditions observed in the infertile female, such
as polycystic ovary syndrome (PCOS) (Koika et al., 2012), endometriosis
(Rahmioglu et al., 2012), and certain anomalies of the female reproduct-
ive system, no diagnostic genetic test is available as these conditions are
multifactorial but there is an increase in the numberof genetic tests being
offered for female infertility.
Genetic testing of femaleswith ovarian insufﬁciency and amenorrhoea
should consist of a chromosomal analysis and fragile X mental
retardation-1 gene (FMR1) ‘expansion’ CGG(n) testing (Foresta et al.,
2002). Other more speciﬁc tests looking for the BPES (blepharophimo-
sis–ptosis-epicanthus inversus) syndrome caused by FOXL2 mutations
(Beysen et al., 2009), galactosemia (GLAT mutations) (Calderon et al.,
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2007) or less commonly POLGmutations (Tong et al., 2010) associated
with a mitochondrial disease should be performed if clinically indicated.
Rarer causes of female infertility, such as those due to mutations in the
FSH-receptor (FSHR) or the LH/CG receptor (LHCGR), should also
be kept in mind and investigated whenever necessary (De Vos et al.,
2010; Persani et al., 2010).Other rarehereditary conditions, such asKall-
mann syndrome (Cadman et al., 2007), androgen insensitivity (Hughes
et al., 2012) and adrenal hyperplasia may be diagnosed as causes of
female infertility (ESHRE-Capri, 2008). In cases of recurrentmiscarriages
(at least three times) (Rull et al., 2012), and for examining balanced trans-
locations and/or other structural anomalies, chromosome analysis
should be performed (ESHRE-Capri, 2008). Inherited thrombophilia
testing requires standardization and further meta-analyses in order to
substantiate its clinical utility (McNamee et al., 2012).
New technologies, such as array comparative genomic hybridization
(aCGH), whole exome sequencing (WES) or whole genome sequencing
(WGS)will likely enable identiﬁcation of additional genes that play an im-
portant role in female reproductive failure (Sykiotis et al., 2010)
Genetic Aspects of Male
Infertility
It has been estimated that roughlyone quarterof patientswith azoosper-
mia (AZ) and severe oligozoospermia undergo genetic testing (Stahl and
Schlegel, 2012). The ﬁrst examination of choice is karyotyping for
common chromosomal aberrations, possibly followed by speciﬁc
molecular tests. Interestingly, the lower the sperm count, the more
chromosomal aberrations are found (Dul et al., 2012).
Gonosomal aberrations are mainly represented by Klinefelter syn-
drome (Maiburg et al., 2012) (47,XXY, including its various mosaic for-
mulae) with a rather heterogeneous clinical presentation. Pathogenic
mutations or variants in the cystic ﬁbrosis transmembrane receptor
gene (CFTR) have been implicated in male infertility (Xu et al., 2007)
and are associated with obstructive AZ due to congenital bilateral
absence of the vas deferens (CBAVD) (Yu et al., 2012).
Various Y chromosome microdeletions are predominantly found in
non-obstructive AZ or severe oligospermia (Simoni et al., 2008). Mo-
lecular genetic diagnosis of such microdeletions is useful and feasible
with a simple and robust test (Simoni et al., 2004). The association to
sperm counts is proportional, in that AZ men have a higher prevalence
of microdeletions than oligospermic patients. Testing of AZF1 microde-
letions has a prognostic impact for sperm extraction, since no sperm can
be retrieved in AZF1a and AZF1b, while there is a fair chance that viable
sperm could be retrieved in AZF1c (Navarro-Costa et al., 2010; Patrat
et al., 2010; Rozen et al., 2012).
Alterations in theGnRH gene (GNRH1), implicated in impaired neur-
onal migration (Kim et al., 2008), were found in congenital hypogonado-
trophic hypogonadism (Sato, 2012).Mutations in the androgen receptor
(AR) gene (Ferlin et al., 2006) are found in 1% of patients with AZ or
severe oligozoospermia. It should be noted that examination of the
entire AR gene is needed.
New technology, such as single nucleotide polymorphism (SNP) var-
iants (Tuttelmann et al., 2007) and genome-wide association studies
(GWAS) (Kosova et al., 2012), has provided evidence that there aremul-
tiple SNPs signiﬁcantly associated with decreased sperm counts (Hu
et al., 2012). At the moment there is no routine ‘diagnostic’ indication
for WES-/WGS-based approaches in male or female infertility (Pastus-
zak and Lamb, 2012).
CounsellingWithin the
Reproductive Medicine and
Genetic Contexts
Genetic counselling is a communication process that involves discussing
the problems associated with a genetic condition (ASHG-GC, 1975;
Resta et al., 2006). A typical genetic counselling consultation encom-
passes the familial, scientiﬁc, psychological and social aspects of being
at risk or being affected. Key concepts in genetic counselling practice
are relevant information exchange, the presentation of choices relevant
to the patient and exploration of patient values and beliefs. In traditional
genetic counselling (of fertile prospective parents), a non-directive
approach is considered to be of paramount importance.
Where genetic risks are related to the causeof infertility, genetic coun-
selling is always required. The cause itself is explained and the implica-
tions for the person’s close relatives (e.g. siblings).
Some couples opt for ART treatment because the fetus is at high risk
for a genetic condition and they wish to avoid termination of pregnancy.
Thereare several options available to couples thatwish to avoidhaving an
affected child; including having no children, having no genetic testing,
having prenatal diagnosis, PGD, using donor gametes, or adoption. For
PGD, genetic counselling should be provided by trained professionals.
PGD and Preimplantation
Genetic Screening
PGD is a diagnostic test used to select genetically or chromosomally
normal embryos for patients at high risk of transmitting a speciﬁc abnor-
mality to their children. Even though these patients will often be fertile,
they have to undergo IVF/ICSI to generate embryos in vitro, which will
be biopsied and these cells will subsequently undergo genetic testing.
The disease or chromosome abnormality needs to be previously identi-
ﬁed, so that speciﬁc (targeted) genetic testing could be performed.
Embryos that are free from the disease tested will be transferred into
the uterus.
Preimplantation genetic screening (PGS) is an adjunct to IVF and is
used to aid embryo selection for certain groups of patients including
thosewith advancedmaternal age, repeated IVF failure, repeatedmiscar-
riage with normal karyotypes in the parents and severe male factor.
For both PGDand PGS, genetic testing can be performed on the polar
bodies, blastomeres from cleavage-stage embryos or trophectoderm
cells from the blastocyst (Harton et al., 2011d).
Historically, twomain techniques have been used for the genetic ana-
lysis in PGD (Harper and Sengupta, 2012): a PCR-based test for single
gene defects (Harton et al., 2011b) and ﬂuorescence in situ hybridization
(FISH) to examine chromosomes (for PGD of translocations and PGS)
(Harton et al., 2011c). More recently, arrays have replaced FISH to
examine chromosomes (Harper and Harton, 2010).
The use of oligo-/SNP arrays (Handyside et al., 2010; Brezina et al.,
2011; Treff et al., 2011) andWES/WGS analyses will allow a substantial
increase in the amount of genetic information that will become available
from each embryo. These rapid technological developments will
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necessitate development of novel guidelines, interpretation algorithms
and ethical frameworks.
PGShas increasingly beenused in thepast decadebutRCTshave failed
to show its effectiveness. PGS RCTs using FISH have been shown to sig-
niﬁcantly reduce the live birth rate (Harper et al., 2010a,b; Mastenbroek
et al., 2011). ESHRE conducted a proof-of-principle study to validate the
use of aCGH for aneuploidy screening (Geraedts et al., 2011) and has
initiated amulti-centre polar bodyRCTusing aCGH for advancedmater-
nal age (ongoing at the time of publication). Three recent RCTs reported
on using new technology for PGS but they have a small sample size and
were conducted on good prognosis patients, not the patients that PGS
would be indicated for (Scott et al., 2012; Yang et al., 2012; Scott et al.,
2013).
The ESHRE PGD Consortium has analysed over 35 000 cycles of
PGD/PGS since 1997 (Goossens et al., 2012; Harper et al., 2012a).
TheConsortium has recently produced four guidelines: the organization
of a PGD/PGS centre, ampliﬁcation-based PGD, FISH-based PGD and
embryology as it relates to PGD and PGS (Harton et al., 2011a,b,c,d).
The Consortium has also produced a guide to PGD laboratory accredit-
ation (Harper et al., 2010a,b).
Genomic Variation in Early
Human Development and
Related Diagnostic Techniques
It is by now well established that chromosomal abnormalities are inher-
ent to human embryos (Delhanty et al., 1993; Munne et al., 1994; Iwars-
son et al., 1999;Munne et al., 2004; Baartet al., 2006;Hodes-Wertz et al.,
2012). Meta-analyses reviewing 36 studies, in which all blastomeres of
cleavage-stage embryos have been analysed by at least eight FISH
probes, show that only 22% of embryos are euploid (van Echten-Arends
et al., 2011), with an increase up to 45% in blastocysts (Fragouli and
Wells, 2011). Considering the mitotic error rate during the cleavage
stage, analysis of single blastomeres will not provide insight in the
genomic constitution of the other cells, nor in the developmental poten-
tial of the embryo (Vanneste et al., 2009; Vanneste et al., 2012).
Single cell WES/WGS sequencing for PGD will provide the most
in-depth view of the human genome at early stages of human develop-
ment (Navin et al., 2011; Spencer and Palmarini, 2012). It is important
to assess the evolutionary, medical, ethical and legal consequences of
these novel technologies in both clinical and community genetics and
assisted human reproduction (Dondorp and de Wert, 2013; Pennings
and Mertes, 2012).
Accreditation of Laboratories in
the Field of Reproductive
Genetics
Theappropriate accreditation standard formedical diagnostic laborator-
ies is ISO 15189 (ISO15189, 2012). Accreditation to this (or an equiva-
lent) is considered as the single most effective route to comprehensive
laboratory quality assurance as stipulated by the Organisation for Eco-
nomic Cooperation and Development (OECD) ‘Guidelines for
Quality Assurance in Genetic testing’ (OECD-QA, 2007). Validation is
a fundamental requirementof ISO15189: ‘Themethods andprocedures
selected for use shall be evaluated and found to give satisfactory results
before being used for medical examinations’.
External quality assessment (EQA) and other methods of inter-
laboratory comparison are a formal requirement of ISO 15189. The
ESHRE PGD Consortium set up a network of partner organizations: (i)
PGD-speciﬁc EQA schemes are now available, (ii) training workshops
addressing the accreditation of PGD laboratories are held regularly,
(iii) the Consortium has formally recommended that all PGD laborator-
ies should be accredited or working actively towards accreditation (ISO
15189) and (iv) a guidance document has been published (Harper et al.,
2010b).
Direct-to-Consumer Genetic
Testing at the Interface of
Genetics and Reproduction
Genetic tests are usually performed in a clinical (medical) genetics centre
with access to counselling (CoE-GenetHealthcare, 2010). In contrast,
within the last several years primarily commercial entities have been in-
creasingly advertising and selling genetic tests either direct-to-consumers
(DTC)orproviding them to their customers in a ‘DTC-through-physician’
(i.e. via a nonspecialist)manner (Hunter et al., 2008; EASC/FEAM report,
2012). DTC genetic testing can be deﬁned as the advertising and selling or
(free) provision of genetic tests directly to consumers.
The range of DTC genetic tests available is broad, including carrier
tests for (i) Mendelian genetic disorders (rare diseases), (ii) ‘life
style’-related genetic traits, (iii) pharmacogenomics, (iv) non-invasive
prenatal testing (v) paternity, (vi) ‘romantic relationship’ testing, (vii)
genomic risk proﬁles formany conditions, or (viii) ‘recreational’ ancestry
or genealogical tests (Howard and Borry, 2011). These different types of
tests bring different practical and ethical concerns (Borry and Howard,
2008).
It is expected that DTC companies will be offeringWES/WGS in the
near future. WGS poses ethical problems, because it basically provides
complete information about an individual genome (Su et al., 2011).
Thismeans that, potentially, every single trait or disorder everassociated
in the past (or ever to be associated with in the future) with a SNP or
other genomic alteration could be identiﬁed.
The commercial offer of carrier testing through the internet creates
various challenges. The large number of disorders that are included in
most of the screening panels contrasts with the limited amount of disor-
ders that are usually suggested to be screened and customers are re-
ferred to their individual physicians for further interpretation of test
results. The majority of these companies ‘disclaim’ any responsibility
for the quality of their service (Borry et al., 2009; Borry et al., 2010;
Howard et al., 2011).
EpigeneticEffectsRelatedtoART
One of the recurrent questions in ART is focused on the issue as to how
much this medical technology could affect the epigenome of human
embryos produced in vitro. The epigenome comprises the complete
set of non-covalent modiﬁcations onto the genetic material of a cell or
anorganism (Yuan, 2012). These epigeneticmarks often affect transcrip-
tional activity and control developmental plasticity of cells, including
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cell-type-speciﬁc gene expression patterns (Jablonka and Raz, 2009; van
Montfoort et al., 2012).
Studies on animalmodels haveestablished that environmental factors,
such as ovulation induction, culture medium composition and/or
embryo manipulation, might affect the epigenome and impact on the
conceptus, including neonatal birthweight. Animal models such as
mouse and cow, commonly suffer fromthe so-called ‘large-offspring syn-
drome’ (Khosla et al., 2001; Young et al., 2001; Velker et al., 2012). In
humans, more studies are needed to corroborate initial discrepant
observations with regard to low birthweight babies following ART
(Dumoulin et al., 2010).
Genomic imprinting is a process through which alleles of given genes
are expressed in a parent-of-origin-speciﬁc manner. Genes that are
subject to imprinting often play key roles in embryonic development
and behaviour. In humans, several defects in imprinted genes are
linked to syndromes such as Beckwith–Wiedemann; MIM #130650),
Prader–Willi (MIM #176270), Angelman (MIM #105830) and Silver–
Russell (MIM #180860). Increased prevalence of imprinting disorders
related to ART has been reported, butmost oftenwithout proper refer-
ence to theprimary causeof infertility andmethods (ICSI, culturemedia).
A summary of the evidence on imprinting and ART shows that absolute
risks appear to be low.
The inﬂuence of ART on the status of the epigenome is not yet com-
pletely understood (OdomandSegars, 2010). ESHREunderstands and is
supporting initiatives for RCTs of culturemedia and their impact on early
epigenetic programming in the embryo. This may also be relevant when
evaluating imprinting defects after ART.
Epidemiological Aspects: Birth
Defects and Population Genetics
ART is associated with a slightly elevated risk of birth defects, multiple
pregnancies (leading topre- and dysmaturity) andmay contribute to an in-
crease of the genetic causes of fertility problems in the future. To evaluate
the pros- and cons of ART, prospective, large cohort, lifelong,multigener-
ational and multi-centre follow-up studies would be extremely important
(Soini et al., 2006), and this issue needs to be addressed at an international
level.
In a systematic review of outcomes after ICSI, eight relevant studies
were identiﬁed, two studying karyotypes and ﬁve reporting malforma-
tions (Odom and Segars, 2010). In total, therewere 55/1973 (2.8%) ab-
normal karyotypes in the ICSI group with ejaculated sperm, 0/31 in the
ICSI group with epididymal sperm and 5/191 (2.6%) in the ICSI group
with testicular sperm. Major malformations were found after ICSI in
543/12 377 (4.4%) in the ejaculated sperm group, 17/533 (3.2%) in
the epididymal sperm group and 31/670 (4.6%) in the testicular sperm
group. While these show that over 95% of infants do not have these
health problems, they have no statistical power to exclude an increase
in speciﬁc birth defects.
A large registry-based study analysing the birth defects registry in the
USA, including 1% of ART in the population and 13,500 infants with birth
defects, reported that among singleton births, ART was associated with
septal heart defects (adjusted odds ratio (aOR) ¼ 2.1, 95% conﬁdence
interval (CI) 1.1–4.0), cleft lip with or without cleft palate (aOR¼ 2.4,
95% CI 1.2–5.1), oesophageal atresia (aOR¼ 4.5, 95% CI 1.9–10.5)
and anorectal atresia (aOR¼ 3.7, 95%CI 1.5–9.1) (Reefhuis et al., 2009).
Outcomes of pregnancies after IVF were studied in Sweden over a
period of 25 years and revealed a decrease ofmultiple pregnancies, a de-
crease of pre-eclampsia and premature rupture of membranes, and an
increased risk for cerebral palsy, possibly for attention deﬁcit and hyper-
activity disorder, for impaired visual acuity and for childhood cancer,
though stressing that these outcomes were generally rare, even after
IVF (Finnstrom et al., 2011).
To decide whether or not increased risk exists, and whether or not
they are avoidable or acceptable, more interdisciplinary research is
needed.
HumanEmbryonicStemCells and
Induced Pluripotent Stem Cells:
Pitfalls and Promises for
Regenerative Medicine and
Disease Modelling
Pluripotency is usually deﬁned as the ability of a cell to differentiate into
derivativesof the three germ layers.Humanembryonic stemcells (hESC)
are the best known example of pluripotent cell lines (Ben-David et al.,
2012), and are for the largest part derived from the inner cell mass of
5- to 6-day old blastocysts. A major breakthrough in the ﬁeld was the
demonstration that terminally differentiated somatic cells could be re-
programmed into a pluripotent state by the induced expression of only
four key pluripotency genes (OCT4, KLF4, SOX2 and C-MYC). Many
observers consider these induced pluripotent stem cells (iPSC) to be
the future replacement of hESC, as they do not carry the negative conno-
tation of embryo research (Tiscornia et al., 2011).
In past years, an increasing bodyof evidence has accumulated showing
that hESC and iPSC suffer from genomic instability that is reminiscent of
cancer cells. They quickly acquire trisomies, especially for chromosomes
12 and 17, small recurrent ampliﬁcations in chromosome 20 (Spits et al.,
2008) and mitochondrial mutations (Van Haute et al., 2013), and their
epigenome changes haphazardly (Amps et al., 2011). Further work is
still needed to establish optimal culture conditions that prevent or limit
this instability. Concurrently, robust and higher throughput screening
tests need to be developed in order to assess the genomic/chromosom-
al stability of stem cells in vitro, both for research, diagnostic, and eventu-
ally for therapeutic purposes.
Equal Access, Prevention of
Infertility, Public Funding of
Assisted Reproduction
Equal access to assisted reproduction for thosewith similar reproductive
needs is still not a reality in Europe. Restrictive national legal provisions
lead to increased CBRC (Shenﬁeld et al., 2010) and create further bar-
riers and social injustice. The EU and its Member State (MS) national
health authorities should enable equal access to ART and PGD, as part
of regular health care and favour education about infertility, genetics
and reproductive options (Pennings et al., 2008a,b; CoE-PGD-PND,
2011).
The adequate role of genetics in health care systems, including promo-
tionof public awarenesson recent advances in genetics andof their impact
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on the general population, were comprehensively outlined in the Council
of Europe (CoE)- ‘Recommendation CM/Rec (2010)11 of the Commit-
tee of Ministers to MS on the impact of genetics on the organization of
health care services and training of health professional’s (CoE-
GenetHealthcare, 2010), in the drafting of which several members of
ESHG and ESHRE were involved.
The ﬁeld has a responsibility to contribute to enlarging access to
assisted reproduction by efforts to increase effectiveness and reduce
costs, especially when services are publicly funded.
Ethical Issues Related to Assisted
Reproduction and Reproductive
Genetics
It is generally accepted that professionals providing medically assisted
reproduction have a responsibility to take account of the welfare
of the future child. According to ESHRE’s Task Force Ethics & Law,
they should refrain from participating in reproduction if there is a high
risk that the future child would have a seriously diminished quality of
life. Professional co-responsibility for the welfare of the child marks an
important difference between the normative framework of medically
assisted reproduction and that of traditional genetic counselling, with
its emphasis on non-directiveness (DeWert, 1999).
PGD is a ﬁeld with many circumstances for discussion about speciﬁc
issues. For instance, PGD for HLA-typing in order to conceive a
‘saviour sibling’ for a child with a life-threatening disorder (Shenﬁeld,
2005), and PGD for disorders caused by a mitochondrial DNA defect
(Bredenoord et al., 2008).
The introductionof newreproductive technologies requiresmoreevi-
dence about their efﬁcacy, safety and cost-effectiveness, as well as long-
term follow up of clinical data (Harper and Sengupta, 2012). Innovations
should ﬁrst be tested in preclinical animal and embryo studies for efﬁcacy
and safety (Harper et al., 2012; Brown andHarper, 2012). Since this may
also require research involving the creation of human embryos, the fact
that this type of embryo research is forbidden in many countries (as well
as by the European Convention on Human Rights and Biomedicine
(Coe-Oviedo, 1997) poses a hurdle for the responsible introduction
of new technologies (Dondorp and deWert, 2011).
Another area at the interface of assisted reproduction and genetics is
the selection of gamete donors. As more diseases with a strong genetic
component arebeing identiﬁed, andas thereare increasing technical cap-
acities todetect them, thequestion ariseswhether thepresent guidelines
for genetic donor screening need revision (Daar and Brzyski, 2009).
Clearly, a ‘zero risk’ approach is unrealistic andmay lead to false reassur-
ance. Relevant ethical issues not only relate to the interests of the pro-
spective parents and the child to be, but also to those of the donor.
Newethical issues can be expected to arise as a result of the introduc-
tion of arrays and WES/WGS in the context of PGD and PGS (Harper
andHarton, 2010;Harper and Sengupta, 2012;Hens et al., 2013).Apos-
sible future scenario is that one ‘universal’ genome analysis will routinely
be offered to all those seeking assisted reproduction, possibly in combin-
ation with preconception testing (Handyside and Xu, 2012). From an
ethical point of view, this not only raises concerns about adequate
pre-test counselling and informed consent, but also requires a further
rethinking of the aims of PGD/PGS (De Wert, 2009). Comprehensive
testing of embryos may lead to ﬁnding predispositions for late onset
disorders for which no adequate options for treatment or prevention
exist. ESHG guidelines stipulate that predictive testing for such disorders
should not be done inminors (Borry et al., 2009; ESHG-Minors, 2009). If
that is the case, would it be acceptable to bring children into the world
with a positive outcome of the same kind of testing? Some of the
moral problems of WES/WGS testing-based PGS may be avoided
with the alternative strategy of offering preconception screening to pro-
spective parents followed by targeted PGD in case of high risk. Obvious-
ly, the ethics of this approach needs further scrutiny (De Wert et al.,
2012).
Legal Issues Related to Assisted
Reproduction and Reproductive
Genetics
Major differences still exist in Europe (CoE-PGD-PND, 2011). PGD is
banned inAustria and Switzerland,whereas jurisprudence and interpret-
ation of laws is affecting practice in Germany (Parliament, 2009), Ireland
and Italy. Allowed indications for PGD vary also in other countries to a
great extent. The diversity of regulation maintains the need for CBRC
(Shenﬁeld et al., 2010) and is pertinent also with regards to the applica-
tion of patient rights in cross-border healthcare (EC-DIR24, 2011).
ECDirective 98/79/EC (EC-Dir98-IVD, 1998) on IVDD (in vitrodiag-
nostic devices) is applicable also to genetic tests, but not to in-house
assays developed and used in the same facility. The Directive is currently
under revision, and it is anticipated that DTC genetic tests will be raised
to a higher risk category meaning that they have to meet more stringent
criteria in the future.
Recently attention has been drawn to the ethical aspects of precon-
ceptional and prenatal genomic testing in many countries, such as by
the Health Council of the Netherlands (Dondorp and de Wert, 2013)
and the Nordic Committee on Bioethics (The Nordic-Bioethics, 2010).
Themainworries relate to the lackof clinical application (within theAna-
lytic validity, Clinical validity, Clinical utility and associated Ethical, legal
and social implications framework for evaluation of genetic tests;
ACCE framework (Haddow, 2003; USA, 2013) for the majority of
tests and the fact that patients/consumers may not receive balanced
pre-test information.
Europe is still fragmented with regards to regulation on ART. The
rulings of ECHR (European Convention on Human Rights) may in time
affect somewhat the states’ margin of appreciation. Until people can
access services in their own countries, CBRC offers a choice, at least
formotivatedwell-informed patientswith the stamina and the necessary
means.
Conclusions
The interface betweenART and genetics has becomemore entwined as
we increaseour understanding about the genetics of infertility andweare
able to perform more comprehensive genetic testing. This continually
evolving ﬁeld requires communication between the clinical genetics,
IVF teams and patients to ensure that they are fully informed and can
make well-considered choices. The genetic basis of male and female in-
fertility will help diagnose the cause of infertility. Also against the back-
ground of reports about possible subtle health effects that may be
related to epigenetic modiﬁcations, there is a growing awareness that
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the introductionof newreproductive technologies and treatments needs
to be based on sound preclinical and clinical research aimed at collecting
evidence about their efﬁcacy and (long-term) safety, as well as their cost-
effectiveness. Comprehensive genetic testing of the embryo before im-
plantation raises complexclinical andethical issues.Couplesmay increas-
ingly undergo awhole genome scan prior to an IVF (or natural) cycle, and
if any serious risk is detected, they can decidewhich reproductive option
would suit thembest. The possibility of performing awhole genome scan
for PGD is around the corner andwould also allow for thedetectionofde
novomutations. As IVF clinics gain higher success rates, and genetic diag-
nosis helps the treatment of infertile couples, therewill need to bemuch
discussion regarding which procedures are clinically and ethically accept-
able and how these are regulated. Through these discussions, we must
develop sound international policies, and facilitate harmonization of le-
gislation and regulatory practices, including equal access to medically
assisted reproduction in Europe, and beyond.
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